NIH Clinical Center logo     America's Clinical Research Hospital File folder iconExplore the NIH
Clinical Center
Search the Studies - NIH Clinical Research Studies

Protocol Details

Brain and Whole Body Imaging of P-Glycoprotein Function Using [11C]dLop

This study is currently recruiting participants.

Summary | Eligibility | Citations | Contacts

Summary

Number

08-M-0062

Sponsoring Institute

National Institute of Mental Health (NIMH)

Recruitment Detail

Type: Participants currently recruited/enrolled
Gender: Male & Female
Min Age: 18
Max Age: 51

Referral Letter Required

No

Population Exclusion(s)

Children

Special Instructions

Currently Not Provided

Keywords

P-Glycoprotein;
Positron Emission Tomography;
Blood Brain Barrier;
Quantitative Imaging;
Multi-Drug Transporter

Recruitment Keyword(s)

Healthy Volunteer;
HV

Condition(s)

Healthy

Investigational Drug(s)

[11C]dLop
XR9576
15O-H2O

Investigational Device(s)

None

Intervention(s)

None

Supporting Site

National Institute of Mental Health

This study will test the use of a radioactive substance called [11C]dLop for measuring P-glycoprotein (P-gp) using positron emission tomography (PET) imaging. The P-gp protein acts as a pump in cells, affecting a variety of functions, such as limiting drug absorption and elimination and decreasing drug penetration into certain tissues, such as the brain. It is a major obstacle to successful chemotherapy because it can pump cancer drugs out of the cells, interfering with treatment. Decreased P-gp function may contribute to disorders such as Parkinson s disease and Alzheimer s disease, whereas higher levels of the protein have been found in patients with epilepsy and in several forms of drug-resistant cancer tumors. This study will determine uptake and clearance of [11C]dLop and the radiation exposure to organs of the body to assess its possible use in further studies of P-gp function.

Healthy normal volunteers between 18 and 51 years of age may be eligible for this study. Candidates are screened with a medical history, physical examination and blood and urine tests.

Participants undergo the following procedures:

-Electrocardiogram (ECG): A test of the electrical function of the heart.

-Brain PET scans: PET imaging uses small amounts of a radioactive chemical called a tracer that labels active areas of the brain so the activity can be seen with a special camera. The tracer used in this study is [18F]FMPEP-d(2). Before starting the scan, a catheter (plastic tube) is placed in a vein in the arm to inject the tracer and another catheter is placed in an artery in the wrist to obtain blood samples during the scan. For the procedure, the subject lies on the scanner bed. A special mask is fitted to the head and attached to the bed to help keep the person s head still during the scan so the images will be clear. A brief scan is done just before the tracer is injected to provide measures of the brain that are helpful in calculating information from subsequent scans. After the tracer is injected, pictures are taken for about 2.5 hours, while the subject lies still on the scanner bed. Blood and urine tests are done after 24 hours after the scan.

-Magnetic resonance imaging (MRI): An MRI scan is done within 1 year (before or after) of the PET scan. This procedure uses a magnetic field and radio waves to produce images of the brain. The subject lies on a table that is moved into the scanner (a tube-like device), wearing earplugs to muffle the noise of the machine during the scanning process. The test takes about 1 hour.

--Back to Top--

Eligibility

DESCRIPTION OF STUDY POPULATIONS:

For the dose escalation study using oral tariquidar, we will select healthy adult female and male volunteers (age 18-51 years old). These healthy volunteers will be medication free, excluding birth control pills. These subjects will be asked to abstain from any medications 16 days before and 1 week after participation in the study.

For the AD study, we will select male and female AD patients and age-matched volunteers who are at least 45 years of age.

INCLUSION CRITERIA:

1. Patients with the diagnosis of probable Alzheimer disease. All patients must meet capacity criteria to consent to research (see Consent documents and process).

2. Healthy volunteers.

EXCLUSION CRITERIA:

1. Current psychiatric disease, illicit substance use, or severe systemic disease based on history and physical exam.

2. Laboratory tests with clinically significant abnormalities. Normal organ and marrow function are defined as: total leukocyte count greater than or equal to 3000 cells/ul, ANC greater than or equal to 1500 cells/ul, platelet count greater than or equal to 100,000 cells/ul, serum creatinine less than or equal to 2.0 times the upper limit of normal, and bilirubin less than or equal to 1.5 times the upper limit of normal, hemoglobin 9.0 g/dL , serum calcium less than or equal to 12.0 mg/dL, AST/ALT less than or equal to 1.5 times the upper limit of normal, PT less than or equal to 1.5 times the upper limit of normal.

3. Prior participation in other research protocols or clinical care in the last year such that radiation exposure including that from this protocol would exceed the guidelines set by the Radiation Safety Committee (RSC).

4. Pregnancy or breast feeding.

5. Positive HIV test.

6. Positive result on urine screen for illicit drugs.

7. You cannot lie on your back for extended periods of time.

8. Use of blood-thinning medications (such as warfarin; aspirin is allowed), current or prior history of coagulopathy. This will be necessary only for subjects who have arterial catheter placement.

9. History of neurological disease other than Alzheimer disease.

10. For oral tariquidar dose-escalation study: Subjects taking medications other than birth control pills.

11. For Alzheimer s disease patients and age-matched volunteers: Subjects taking medications that are known substrates of P-gp that cannot be safely discontinued for this study.


--Back to Top--

Citations:

Awouters F, Niemegeers CJ, Janssen PA. Pharmacology of antidiarrheal drugs. Annu Rev Pharmacol Toxicol. 1983;23:279-301.

Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci. 2000 Dec;3(12):1301-6.

Bigott HM, Prior JL, Piwnica-Worms DR, Welch MJ. Imaging multidrug resistance P-glycoprotein transport function using microPET with technetium-94m-sestamibi. Mol Imaging. 2005 Jan-Mar;4(1):30-9.

--Back to Top--

Contacts:

Principal Investigator

Referral Contact

For more information:

William C. Kreisl, M.D.
National Institute of Mental Health (NIMH)
BG 10 RM B1D43
10 CENTER DR
BETHESDA MD 20814
(301) 451-8894
kreislw@mail.nih.gov

Emily M. Page, C.R.N.P.
National Institute of Mental Health (NIMH)
BG 10 RM B1D43
10 CENTER DR
BETHESDA MD 20814
(301) 451-7904
emily.page@nih.gov

Patient Recruitment and Public Liaison Office
Building 61
10 Cloister Court
Bethesda, Maryland 20892-4754
Toll Free: 1-800-411-1222
TTY: 301-594-9774 (local),1-866-411-1010 (toll free)
Fax: 301-480-9793

prpl@mail.cc.nih.gov

Clinical Trials Number:

NCT00605254

--Back to Top--

QUESTIONS?

Contact the Patient Recruitment and Public Liaison Office for:

  • Details on how to participate in a study
  • Details on how to refer a patient to a study

NIH Clinical Studies Information Request


Contact the Office of Communications for:

  • General information about the NIH Clinical Center

www.cc.nih.gov/contact.shtml


Contact the Department Clinical Research Informatics, (DCRI) for:

  • Technical questions about Adobe Acrobat and the PDF format
  • Technical questions about this web server

webmaster@cc.nih.gov